Recursion Pharmaceuticals Stock

Recursion Pharmaceuticals Equity

The The Equity of Recursion Pharmaceuticals (RXRX) as of Aug 5, 2026 is 1.13 B USD. In the previous year, The Equity was 1.03 B USD — a change of 9.29% (higher).

Equity

1.13 BUSD

YoY

9.29%

Last updated:

In 2026, Recursion Pharmaceuticals's equity was 1.13 B USD, a 9.29% increase from the 1.03 B USD equity in the previous year.

Access this data via the Eulerpool API
Get Free API Key

Recursion Pharmaceuticals Stock analysis

What does Recursion Pharmaceuticals do? Recursion Pharmaceuticals is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Recursion Pharmaceuticals's Equity

Recursion Pharmaceuticals's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Recursion Pharmaceuticals's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Recursion Pharmaceuticals's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Recursion Pharmaceuticals's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Recursion Pharmaceuticals’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Recursion Pharmaceuticals stock

The Equity of Recursion Pharmaceuticals is 1.13 B USD in 2026.

The Equity of Recursion Pharmaceuticals changed from 1.03 B USD to 1.13 B USD, representing a 9.29% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Equity Recursion Pharmaceuticals since 2006 – with annual values, charts, and detailed analysis.

The Equity's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Recursion Pharmaceuticals historically and in real time.

Access this data via the Eulerpool API
Get Free API Key

Balance Sheet — Recursion Pharmaceuticals

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Recursion Pharmaceuticals